| Autor: |
Kienesberger B; Department of Paediatric and Adolescent Surgery, Medical University of Graz, 8036 Graz, Austria., Obermüller B; Department of Paediatric and Adolescent Surgery, Medical University of Graz, 8036 Graz, Austria., Singer G; Department of Paediatric and Adolescent Surgery, Medical University of Graz, 8036 Graz, Austria., Mittl B; Department of Paediatric and Adolescent Surgery, Medical University of Graz, 8036 Graz, Austria., Grabherr R; Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, 1190 Vienna, Austria., Mayrhofer S; Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, 1190 Vienna, Austria., Heinl S; Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, 1190 Vienna, Austria., Stadlbauer V; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, 8036 Graz, Austria., Horvath A; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, 8036 Graz, Austria.; Center of Biomarker Research (CBmed), 8036 Graz, Austria., Miekisch W; Experimental Research Center, Department of Anesthesiology and Intensive Care, Rostock University Medical Center, 18057 Rostock, Germany., Fuchs P; Experimental Research Center, Department of Anesthesiology and Intensive Care, Rostock University Medical Center, 18057 Rostock, Germany., Klymiuk I; Gottfried Schatz Research Center, Department of Cell Biology, Histology and Embryology, Medical University of Graz, 8036 Graz, Austria., Till H; Department of Paediatric and Adolescent Surgery, Medical University of Graz, 8036 Graz, Austria., Castellani C; Department of Paediatric and Adolescent Surgery, Medical University of Graz, 8036 Graz, Austria. |
| Abstrakt: |
We aimed to assess the in vitro antimicrobial activity and the in vivo effect on the murine fecal microbiome and volatile organic compound (VOC) profile of (S)-reutericyclin. The antimicrobial activity of (S)-reutericyclin was tested against Clostridium difficile , Listeria monocytogenes , Escherichia coli , Enterococcus faecium , Staphylococcus aureus , Staphylococcus (S.) epidermidis , Streptococcus agalactiae , Pseudomonas aeruginosa and Propionibacterium acnes . Reutericyclin or water were gavage fed to male BALBc mice for 7 weeks. Thereafter stool samples underwent 16S based microbiome analysis and VOC analysis by gas chromatography mass spectrometry (GC-MS). (S)-reutericyclin inhibited growth of S. epidermidis only. Oral (S)-reutericyclin treatment caused a trend towards reduced alpha diversity. Beta diversity was significantly influenced by reutericyclin. Linear discriminant analysis Effect Size (LEfSe) analysis showed an increase of Streptococcus and Muribaculum as well as a decrease of butyrate producing Ruminoclostridium , Roseburia and Eubacterium in the reutericyclin group. VOC analysis revealed significant increases of pentane and heptane and decreases of 2,3-butanedione and 2-heptanone in reutericyclin animals. The antimicrobial activity of (S)-reutericyclin differs from reports of (R)-reutericyclin with inhibitory effects on a multitude of Gram-positive bacteria reported in the literature. In vivo (S)-reutericyclin treatment led to a microbiome shift towards dysbiosis and distinct alterations of the fecal VOC profile. |
